Pediatric Rheumatology Online Journal (Oct 2022)

Tumor necrosis factor inhibitors for pediatric patients with SAPHO syndrome associated with acne conglobata

  • Shengyan Liu,
  • Xia Wu,
  • Yihan Cao,
  • Zhaohui Li,
  • Yuchen Liu,
  • Mingwei Ma,
  • Chen Li

DOI
https://doi.org/10.1186/s12969-022-00749-9
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 3

Abstract

Read online

Abstract Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease with osteoarticular and cutaneous involvements as its main manifestations. Acne conglobata as a severe acne form may affect adolescent patients. Tumor necrosis factor inhibitors are usually used as a second-line therapy for refractory SAPHO syndrome and has been reported to treat acne conglobata successfully. We herein report three cases of adolescent patients with SAPHO syndrome associated with acne conglobata who were successfully treated with TNFi therapy.

Keywords